Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8+T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency Reversal

Abstract excerpt

Antiretroviral (ARV) drug regimens suppress HIV-1 replication but are unable to cure infection. This leaves people living with HIV-1 burdened by a lifelong commitment to expensive daily medication. Furthermore, it has become clear that ARV therapy does not fully restore health, leaving individuals at elevated risk for cardiovascular disease, certain types of cancers, and neurocognitive disorders, as well as...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HIV/AIDS drug development and treatment
• Share to HIV/AIDS Research and Interventions